News Daily News It’s Official: Evolocumab Gains Claim for CVD Event Reduction Michael O'Riordan December 04, 2017
News Conference News AHA 2017 Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI Yael L. Maxwell November 13, 2017
News Daily News Evolocumab ‘Abjectly Fails’ Another Financial Stress Test Michael O'Riordan October 19, 2017
News Daily News Secondary Prevention Lagging Behind in Women With Established Coronary Disease Todd Neale September 22, 2017
News Industry News New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes September 15, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017
News Daily News ‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low Michael O'Riordan August 01, 2017
News Daily News Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients Yael L. Maxwell April 11, 2017
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017
News Conference News ACC 2017 SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ISC 2017 Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned Todd Neale February 24, 2017
News Daily News Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint Michael O'Riordan February 03, 2017